M. Horner, National Cancer Institute, Cancer Statistics Review, 1975.

D. Geynisman and K. Wickersham, Adherence to targeted oral anticancer medications, Discov Med, vol.15, pp.231-241, 2013.

G. Banna, E. Collovà, and V. Gebbia, Anticancer oral therapy: Emerging related issues, Cancer Treatment Reviews, vol.36, issue.8, pp.595-605, 2010.
DOI : 10.1016/j.ctrv.2010.04.005

F. Bassan, F. Peter, and B. Houbre, Adherence to oral antineoplastic agents by cancer patients: definition and literature review, European Journal of Cancer Care, vol.50, issue.11, pp.22-35, 2014.
DOI : 10.1111/ecc.12124

D. Cremoux, P. Diéras, V. Poupon, and M. , Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects, Bull Cancer, vol.91, pp.917-927, 2004.

M. Dowsett, J. Cuzick, and J. Ingle, Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen, Journal of Clinical Oncology, vol.28, issue.3, pp.509-518, 2010.
DOI : 10.1200/JCO.2009.23.1274

P. Lønning and H. Eikesdal, Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved, Endocrine Related Cancer, vol.20, issue.4, pp.183-201, 2013.
DOI : 10.1530/ERC-13-0099

P. Pfeiffer, J. Mortensen, and B. Bjerregaard, Patient preference for oral or intravenous chemotherapy: A randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer, European Journal of Cancer, vol.42, issue.16, pp.2738-2743, 2006.
DOI : 10.1016/j.ejca.2006.06.027

F. Palmieri and D. Barton, Challenges of Oral Medications in Patients With Advanced Breast Cancer, Seminars in Oncology Nursing, vol.23, pp.17-22, 2007.
DOI : 10.1016/j.soncn.2007.10.004

V. Regnier-denois, J. Poirson, and F. Soum-pouyalet, Oral anti-cancer chemotherapy: social representations and medical practices, Psycho-Oncologie, vol.25, issue.2, pp.168-175, 2009.
DOI : 10.1007/s11839-009-0140-2

R. Denois, V. Poirson, J. Nourissat, and A. , Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists, European Journal of Cancer Care, vol.366, issue.4, pp.520-527, 2011.
DOI : 10.1111/j.1365-2354.2010.01212.x

V. Foulon, P. Schöffski, and P. Wolter, Patient adherence to oral anticancer drugs: an emerging issue in modern oncology, Acta Clin Belg, vol.66, pp.85-96, 2011.

J. Cramer, A. Roy, and A. Burrell, Medication Compliance and Persistence: Terminology and Definitions, Value in Health, vol.11, issue.1, pp.44-47, 2008.
DOI : 10.1111/j.1524-4733.2007.00213.x

C. Wahl, J. Gregoire, and K. Teo, Concordance, Compliance and Adherence in Healthcare: Closing Gaps and Improving Outcomes, Healthcare Quarterly, vol.8, issue.1, pp.65-70, 2005.
DOI : 10.12927/hcq..16941

A. Lamouroux, A. Magnan, and D. Vervloet, Compliance, observance ou adhésion thérapeutique Rev mal respi, pp.31-34, 2005.
DOI : 10.1016/s0761-8425(05)85433-6

L. Osterberg and T. Blaschke, Adherence to Medication, New England Journal of Medicine, vol.353, issue.5, pp.487-497, 2005.
DOI : 10.1056/NEJMra050100

S. Spoelstra and C. Given, Assessment and Measurement of Adherence to Oral Antineoplastic Agents, Seminars in Oncology Nursing, vol.27, issue.2, pp.116-132, 2011.
DOI : 10.1016/j.soncn.2011.02.004

C. Droz-perroteau, La persistance des traitements en vie réelle comme mesure d'impact en pharmacoépidémiologie, Thèse d'exercice

F. Bassan, F. Peter, and B. Houbre, Adherence to oral antineoplastic agents by cancer patients: definition and literature review, European Journal of Cancer Care, vol.50, issue.11, pp.22-35, 2014.
DOI : 10.1111/ecc.12124

R. Tamblyn, G. Lavoie, and L. Petrella, The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Qu??bec, Journal of Clinical Epidemiology, vol.48, issue.8, pp.999-1009, 1995.
DOI : 10.1016/0895-4356(94)00234-H

J. Steiner, T. Koepsell, and S. Fihn, A General Method of Compliance Assessment Using Centralized Pharmacy Records, Medical Care, vol.26, issue.8, pp.814-823, 1988.
DOI : 10.1097/00005650-198808000-00007

J. Steiner and A. Prochazka, The assessment of refill compliance using pharmacy records: Methods, validity, and applications, Journal of Clinical Epidemiology, vol.50, issue.1, pp.105-116, 1997.
DOI : 10.1016/S0895-4356(96)00268-5

P. Tuppin, L. De-roquefeuil, and A. Weill, French national health insurance information system and the permanent beneficiaries sample, Revue d'??pid??miologie et de Sant?? Publique, vol.58, issue.4, pp.286-290, 2010.
DOI : 10.1016/j.respe.2010.04.005

D. Roquefeuil, L. Studer, A. Neumann, and A. , The Echantillon généralistes de bénéficiaires : representativeness, scope and limits, Pratique et organisation des soins, vol.43, pp.213-233, 2009.

S. Andrade, K. Kahler, and F. Frech, Methods for evaluation of medication adherence and persistence using automated databases, Pharmacoepidemiology and Drug Safety, vol.9, issue.8, pp.565-574, 2006.
DOI : 10.1002/pds.1230

C. Murphy, L. Bartholomew, and M. Carpentier, Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review, Breast Cancer Research and Treatment, vol.28, issue.27, pp.459-478, 2012.
DOI : 10.1007/s10549-012-2114-5

L. Huiart, C. Ferdynus, and G. R. , A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians, Breast Cancer Research and Treatment, vol.32, issue.3, pp.325-328, 2013.
DOI : 10.1007/s10549-013-2422-4

P. Bosco-lévy, Evaluation de l'adhérence aux hormonothérapies orales prescrites dans le traitement du cancer du sein, Master Recherche Epidémiologie et Recherche Clinique, pp.2014-60

P. Bosco-lévy, J. Jove, and P. Robinson, Persistence to five-year hormonal breast cancer therapy: A French nationwide population-based study

M. Verbrugghe, S. Verhaeghe, and K. Lauwaert, Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: A systematic review, Cancer Treatment Reviews, vol.39, issue.6, pp.610-621, 2013.
DOI : 10.1016/j.ctrv.2012.12.014

M. Puts, H. Tu, and A. Tourangeau, Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review, Annals of Oncology, vol.25, issue.3, pp.564-577, 2014.
DOI : 10.1093/annonc/mdt433

D. Hershman, T. Shao, and L. Kushi, Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer, Breast Cancer Research and Treatment, vol.44, issue.5, pp.529-566, 2011.
DOI : 10.1007/s10549-010-1132-4

B. Makubate, P. Donnan, and J. Dewar, Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality, British Journal of Cancer, vol.378, issue.7, pp.1515-1539, 2013.
DOI : 10.1093/annonc/mdn646

C. Mccowan, J. Shearer, and P. Donnan, Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer, British Journal of Cancer, vol.206, issue.11, pp.1763-1771, 2008.
DOI : 10.1038/sj.bjc.6604758

M. Yood, C. Owusu, and D. Buist, Mortality Impact of Less-than-Standard Therapy in Older Breast Cancer Patients, Journal of the American College of Surgeons, vol.206, issue.1, pp.66-75, 2008.
DOI : 10.1016/j.jamcollsurg.2007.07.015

K. Hsieh, L. Chen, and K. Cheung, Interruption and Non-Adherence to Long-Term Adjuvant Hormone Therapy Is Associated with Adverse Survival Outcome of Breast Cancer Women - An Asian Population-Based Study, PLoS ONE, vol.44, issue.2, p.87027, 2014.
DOI : 10.1371/journal.pone.0087027.t003

C. Mccowan, S. Wang, and A. Thompson, The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study, British Journal of Cancer, vol.4, issue.5, pp.1172-80, 2013.
DOI : 10.1016/j.jamcollsurg.2007.07.015

E. Wu, A. Guerin, and A. Yu, Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia, Current Medical Research and Opinion, vol.26, issue.12, pp.2861-2869, 2010.
DOI : 10.1185/03007995.2010.533648

T. Darkow, H. Henk, and S. Thomas, Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs, PharmacoEconomics, vol.52, issue.5, pp.481-496, 2007.
DOI : 10.2165/00019053-200725060-00004

K. Lui, ESTIMATION OF SAMPLE SIZES IN CASE-CONTROL STUDIES WITH MULTIPLE CONTROLS PER CASE: DICHOTOMOUS DATA1, American Journal of Epidemiology, vol.127, issue.5, pp.1064-1070, 1988.
DOI : 10.1093/oxfordjournals.aje.a114882

C. Early-breast and . Trialists, Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women, Lancet, vol.339, pp.71-85

V. Ziller, M. Kalder, and U. Albert, Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer, Annals of Oncology, vol.20, issue.3, pp.431-436, 2009.
DOI : 10.1093/annonc/mdn646

T. Barron, R. Connolly, and K. Bennett, Early discontinuation of tamoxifen, Cancer, vol.12, issue.5, pp.832-839, 2007.
DOI : 10.1002/cncr.22485

A. Ma, J. Barone, and A. Wallis, Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients, The American Journal of Surgery, vol.196, issue.4, pp.500-504, 2008.
DOI : 10.1016/j.amjsurg.2008.06.027

C. Owusu, D. Buist, and T. Field, Predictors of Tamoxifen Discontinuation Among Older Women With Estrogen Receptor???Positive Breast Cancer, Journal of Clinical Oncology, vol.26, issue.4, pp.549-555, 2008.
DOI : 10.1200/JCO.2006.10.1022

M. Van-herk-sukel, L. Van-de-poll-franse, and A. Voogd, Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5??years: a population-based analysis, Breast Cancer Research and Treatment, vol.20, issue.3, pp.843-851, 2010.
DOI : 10.1007/s10549-009-0724-3

A. Partridge, P. Wang, and E. Winer, Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer, Journal of Clinical Oncology, vol.21, issue.4, pp.602-606, 2003.
DOI : 10.1200/JCO.2003.07.071

K. Weaver, F. Camacho, and W. Hwang, Adherence to Adjuvant Hormonal Therapy and Its Relationship to Breast Cancer Recurrence and Survival Among Low-income Women, American Journal of Clinical Oncology, vol.36, issue.2, pp.181-188, 2013.
DOI : 10.1097/COC.0b013e3182436ec1

N. Breslow, N. Day, and K. Halvorsen, ESTIMATION OF MULTIPLE RELATIVE RISK FUNCTIONS IN MATCHED CASE-CONTROL STUDIES, American Journal of Epidemiology, vol.108, issue.4, pp.299-307, 1978.
DOI : 10.1093/oxfordjournals.aje.a112623

S. Greenland and D. Thomas, ON THE NEED FOR THE RARE DISEASE ASSUMPTION IN CASE-CONTROL STUDIES, American Journal of Epidemiology, vol.116, issue.3, pp.547-53, 1982.
DOI : 10.1093/oxfordjournals.aje.a113439

N. Pearce, What Does the Odds Ratio Estimate in a Case-Control Study?, International Journal of Epidemiology, vol.22, issue.6, pp.1189-92, 1993.
DOI : 10.1093/ije/22.6.1189

P. Hadji, Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy, Critical Reviews in Oncology/Hematology, vol.73, issue.2, pp.156-166, 2010.
DOI : 10.1016/j.critrevonc.2009.02.001

K. Ruddy, E. Mayer, and A. Partridge, Patient adherence and persistence with oral anticancer treatment, CA: A Cancer Journal for Clinicians, vol.59, issue.1, pp.56-66, 2009.
DOI : 10.3322/caac.20004

R. Sikka, F. Xia, and R. Aubert, Estimating medication persistency using administrative claims data, Am J Manag Care, vol.11, pp.449-457, 2005.

R. Grymonpre, M. Cheang, and M. Fraser, Validity of a Prescription Claims Database to Estimate Medication Adherence in Older Persons, Medical Care, vol.44, issue.5, pp.471-478, 2006.
DOI : 10.1097/01.mlr.0000207817.32496.cb

H. Lau, A. De-boer, and K. Beuning, Validation of pharmacy records in drug exposure assessment, Journal of Clinical Epidemiology, vol.50, issue.5, pp.619-625, 1997.
DOI : 10.1016/S0895-4356(97)00040-1

L. Hess, M. Raebel, and D. Conner, Measurement of Adherence in Pharmacy Administrative Databases: A Proposal for Standard Definitions and Preferred Measures, Annals of Pharmacotherapy, vol.38, issue.3, pp.1280-1288, 2006.
DOI : 10.1345/aph.1H018

P. Noize, F. Bazin, and C. Dufouil, Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study, Pharmacoepidemiology and Drug Safety, vol.47, issue.4, pp.310-319, 2009.
DOI : 10.1159/000072920

S. Schneeweiss, J. Seeger, and M. Maclure, Performance of Comorbidity Scores to Control for Confounding in Epidemiologic Studies using Claims Data, American Journal of Epidemiology, vol.154, issue.9, pp.854-864, 2001.
DOI : 10.1093/aje/154.9.854

S. Demissie, R. Silliman, and T. Lash, Adjuvant Tamoxifen: Predictors of Use, Side Effects, and Discontinuation in Older Women, Journal of Clinical Oncology, vol.19, issue.2, pp.322-328, 2001.
DOI : 10.1200/JCO.2001.19.2.322